Alzamend Neuro, Inc.
ALZN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001677077
In the last 90 days, Alzamend Neuro, Inc. insiders filed 1 open-market purchase and 1 sale; 12 institutions reported holding it in 13F filings for Q2 2026, worth $3.26M in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Alzamend Neuro, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 0 | 11 | +11 |
| Shares | 0 | 295.7K | +295.7K |
| Value | $0 | $2.58M | +$2.58M |
New holders (11)
Institutions that held Alzamend Neuro, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jane Street Group, LLC | 133,725 | $1.17M | 0.00% |
| Susquehanna International Group, LLP | 57,030 | $498.0K | 0.00% |
| Geode Capital Management, LLC | 44,600 | $389.0K | 0.00% |
| Cubist Systematic Strategies, LLC | 23,672 | $207.0K | 0.00% |
| Two Sigma Securities, LLC | 16,018 | $140.0K | 0.04% |
| Virtu Financial LLC | 15,402 | $135.0K | 0.01% |
| UBS Group AG | 2,691 | $24.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 2,045 | $18.0K | 0.00% |
| Wells Fargo & Company | 193 | $2.00K | 0.00% |
| Morgan Stanley | 259 | $2.00K | 0.00% |
| Advisor Group Holdings, Inc. | 27 | $0 | 0.00% |
Sold out (0)
Institutions that held Alzamend Neuro, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
None.